Mineralys Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
FMR LLC, through its subsidiaries, has reported beneficial ownership of 5.1% of Mineralys Therapeutics Inc.'s common stock as of June 30, 2026.
NASDAQ
FMR LLC and its Chairman and CEO, Abigail P. Johnson, have disclosed a 6.3% beneficial ownership stake in Mineralys Therapeutics Inc. as of December 31, 2025.
NASDAQ
SCHEDULE 13G: BlackRock Discloses 5.2% Stake in Mineralys Therapeutics
BlackRock, Inc. has reported a significant passive ownership stake of 5.2% in Mineralys Therapeutics Inc., holding over 4.1 million shares of common stock.
NASDAQ
SCHEDULE 13G/A: Catalys Pacific Maintains 13.5% Stake in Mineralys Therapeutics
Catalys Pacific and its affiliates reported continued beneficial ownership of 13.5% of Mineralys Therapeutics, Inc.'s common stock as of June 30, 2025.
NASDAQ
Andera Partners and affiliates report a reduced beneficial ownership of Mineralys Therapeutics, Inc. common stock to 4.2%.
NASDAQ
Adams Street Partners, LLC and its affiliated funds have filed an amended Schedule 13G, reporting a collective passive beneficial ownership of 2.3% in Mineralys Therapeutics, Inc.'s common stock as of December 31, 2024.